Financial Lp Hrt Sells 10,580 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 10,580 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.33, for a total transaction of $35,231.40. Following the completion of the sale, the insider owned 70,805 shares of the company’s stock, valued at approximately $235,780.65. This trade represents a 13.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.52, for a total transaction of $65,229.12.
• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.51, for a total value of $31,667.22.
• On Thursday, July 2nd, Financial Lp Hrt purchased 7,851 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.54 per share, for a total transaction of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt acquired 3,959 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average price of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt purchased 6,755 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average price of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Trading Down 11.0%

SHPH opened at $2.92 on Friday. Shuttle Pharmaceuticals Holdings, Inc. has a 1-year low of $2.90 and a 1-year high of $55.90. The business has a 50 day moving average of $5.01 and a 200-day moving average of $10.13. The stock has a market capitalization of $1.87 million, a price-to-earnings ratio of -0.06 and a beta of 0.29.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in SHPH. Connective Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals during the third quarter worth approximately $357,000. Geode Capital Management LLC bought a new position in Shuttle Pharmaceuticals during the fourth quarter worth about $26,000. Boothbay Fund Management LLC bought a new stake in shares of Shuttle Pharmaceuticals in the 4th quarter valued at about $37,000. Finally, Ikarian Capital LLC acquired a new position in Shuttle Pharmaceuticals during the fourth quarter valued at approximately $124,000. Institutional investors own 4.58% of the company’s stock.

Analyst Upgrades and Downgrades

SHPH has been the subject of several research reports. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday, July 4th. Weiss Ratings raised Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .